Nuvectis Pharma, Inc. (NVCT) Income Statement
NVCT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNVCT revenue and net income
NVCT profit margins
NVCT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NVCT quarterly EPS vs estimates
Nuvectis Pharma beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 3, 2026 (estimate $-0.22).
NVCT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $149,000 | $0 | $0 |
| Cost of revenue | — | — | $22.9M | $19.2M | $12.9M | — |
| Gross profit | — | — | −$22.9M | −$19.1M | −$12.9M | — |
| Research & development | $18.2M | $12.9M | $15.4M | $13.2M | $9.5M | — |
| Sales, general & admin | $9.4M | $6.9M | $7.5M | $6.0M | $3.3M | $24,000 |
| Total operating expenses | $27.6M | $19.8M | $22.9M | $19.2M | $12.9M | $10,000 |
| Operating income | −$27.6M | −$19.8M | −$22.9M | −$19.2M | −$12.9M | −$10,000 |
| Interest income | $1.1M | $847,000 | $475,000 | $149,000 | $4,000 | — |
| Interest expense | — | — | — | $149,000 | $4,000 | $0 |
| Income before taxes | −$26.4M | −$19.0M | −$22.3M | −$19.1M | −$12.9M | −$10,000 |
| Income taxes | — | −$19.0M | $1,000 | −$298,000 | −$4,000 | −$24 |
| Net income | −$26.4M | −$19.0M | −$22.3M | −$18.8M | −$12.9M | −$10,000 |
| EBITDA | −$26.4M | −$19.0M | −$22.3M | −$18.9M | −$12.9M | −$10,000 |
| EPS (diluted) | −$1.32 | −$1.10 | −$1.43 | −$1.51 | −$24.91 | $0.00 |
| Gross margin | — | — | — | −12,808.7% | — | — |
| Operating margin | — | — | — | −12,908.7% | — | — |
| Net margin | — | — | — | −12,608.7% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $26.8M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | $13.4M | $4.4M | $4.6M | $4.4M | $11.0M | $6.2M |
| Gross profit | — | — | — | — | — | — | $13.4M | −$4.4M | −$4.6M | −$4.4M | −$15.1M | −$6.2M |
| Research & development | $4.7M | $4.1M | $5.1M | $5.8M | $3.6M | $3.7M | $4.5M | $2.8M | $2.9M | $2.7M | $4.3M | $4.5M |
| Sales, general & admin | $2.5M | $2.2M | $2.5M | $2.0M | $3.0M | $1.9M | $2.0M | $1.5M | $1.7M | $1.7M | $2.6M | $1.7M |
| Total operating expenses | $7.2M | $6.3M | $7.6M | $7.8M | $6.6M | $5.6M | $6.4M | $4.4M | $4.6M | $4.4M | $6.9M | $6.2M |
| Operating income | −$7.2M | −$6.3M | −$7.6M | −$7.8M | −$6.6M | −$5.6M | −$6.4M | −$4.4M | −$4.6M | −$4.4M | −$6.9M | −$6.2M |
| Interest income | $177,000 | $210,000 | $303,000 | $332,000 | $261,000 | $236,000 | $201,000 | $206,000 | $215,000 | $225,000 | $244,000 | $277,000 |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $52,000 | — |
| Income before taxes | −$7.0M | −$6.0M | −$7.3M | −$7.5M | −$6.3M | −$5.3M | −$6.2M | −$4.2M | −$4.4M | −$4.2M | −$6.6M | −$5.9M |
| Income taxes | — | — | — | — | — | — | — | — | — | −$43,277 | $1,000 | $6.2M |
| Net income | −$7.0M | −$6.0M | −$7.3M | −$7.5M | −$6.3M | −$5.3M | −$6.2M | −$4.2M | −$4.4M | −$4.2M | −$6.6M | −$5.9M |
| EBITDA | −$7.2M | −$6.0M | −$8.2M | −$7.5M | −$6.3M | −$5.3M | −$6.2M | −$4.2M | −$4.4M | −$4.2M | −$6.6M | −$5.9M |
| EPS (diluted) | −$0.30 | −$0.26 | −$0.31 | −$0.44 | −$0.30 | −$0.27 | −$0.35 | −$0.24 | −$0.26 | −$0.25 | −$0.41 | −$0.37 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −24.1% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −23.3% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NVCT's financial statements (latest annual report filed February 11, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NVCT financial results
Nuvectis Pharma reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $26.4 million. Diluted earnings per share came to −$1.32.
See the NVCT stock overview for the latest quote and news, or the NVCT chart for price history and technical indicators.
NVCT income statement FAQ
Does Nuvectis Pharma have revenue?
Nuvectis Pharma reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Nuvectis Pharma profitable?
No. Nuvectis Pharma reported a net loss of $26.4 million in fiscal 2025.
How much does Nuvectis Pharma spend on research and development?
Nuvectis Pharma spent $18.2 million on research and development in fiscal 2025.
What are Nuvectis Pharma's earnings per share?
Nuvectis Pharma earned $-1.32 per diluted share in fiscal 2025, compared with $-1.10 a year earlier.
When will Nuvectis Pharma report its next earnings?
Nuvectis Pharma is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens.
When does Nuvectis Pharma's fiscal year end?
Nuvectis Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 11, 2026.